The Care of the Lung Cancer Patient in the 21st Century: A New Age

Seminars in Oncology

Volumn 31, Issue 2 SUPPL. 4, 2004, Pages 11-15

  Smith, Wade ^a   Khuri, Fadlo R ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEFITINIB; GROWTH FACTOR RECEPTOR; IFOSFAMIDE; LOMUSTINE; LONAFARNIB; METHOTREXATE; MITOMYCIN; TEGAFUR; URACIL; VINDESINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; GENE TARGETING; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; ONCOGENE; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROTEIN TARGETING; SURGICAL TECHNIQUE; TUMOR SUPPRESSOR GENE; UNITED STATES;

EID: 2342549269     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.02.012     Document Type: Conference Paper

References (30)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003
2. Steward BW, Kleihues P: Lung cancer, in Stewart BW, Kleihues P (eds): World Cancer Report. Lyon, France, IARC Press, 2003, pp 182-187
3. Schottenfield D: Epidemiology of lung cancer, in Pass HI, Mitchell JB, Johnson DH (eds): Lung Cancer Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1996, pp 305-321
4. Khuri FR, Herbst RS, Fossella FV: Emerging therapies in non-small-cell lung cancer. Ann Oncol 12:739-744, 2001
5. Rapp E, Willan A, Cormies Y, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-Report of a Canadian multi-center randomized trial. J Clin Oncol 6:633-641, 1988
6. Woods RL, Williams CJ, Levi J, et al: A randomized trial of cisplatin and vindesin versus supportive care only in advanced non-small-cell lung cancer. Br J Cancer 61:608-611, 1990
7. Quoix E, Dietemann A, Charbonneau J, et al: Is chemotherapy with cisplatin useful in non small cell bronchial cancer at staging IV. Bull Cancer 78:341-346, 1991
8. Ganz PA, Figlin RA, Haskell CM, et al: Supportive care versus supportive care and combination chemotherapy in metastatic non-small-cell lung Cancer. Does chemotherapy make a difference? Cancer 63:1271-1278, 1989
9. Cartei G, Cartei F, Cantone A, et al: Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care vs. supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst 85:794-800, 1993
10. Cellerino R, Tummarello D, Guidi F, et al: A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 9:1453-1461, 1991
11. Cullen MH, Joshi R, Chetiyawandana AD, et al: Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer: Treatment good enough to compare. Br J Cancer 58:359-361, 1988
12. Helsing M, Bergman B, Thaning L, et al: Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicenter randomized phase III trial. Joint Lung Cancer Study group. J Cancer 34:1036-1044, 1998
13. Noda K, Nishiwaki Y, Kawahara M, et al, Japan Clinical Oncology Group: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
14. Schiller JH, Harrington D, Belani CP, et al, Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl Med 346:92-98, 2002
15. Fossella F, Pereira JR, von Pawel J, et al: Randomized, multinational phase 3 study of docetaxel plus platinum combination vs. vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 Study Group. J Clin Oncol 21:3016-3024, 2003
16. Turissi AT, Kim K, Blun R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999
17. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990
18. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
19. Curran WJ Jr, Scott C, Bonomi P, et al: Initial report of locally advanced multimodality protocol (LAMP): ACR 427: A randomized 3-arm phase II study of Pactitaxel (T), Carboplatin (C), and thoracic radiation (TRT) for patients with stage III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:312(abstr 1244), 2001
20. Gandara DR, Chansky K, Albain KS, et al, Southwest Oncology Group: Consolidation docetaxel after noncurrent chemoradiotherapy in stage 3b non-small-cell lung cancer: Phase 2 Southwest Oncology Group Study S9504. J Clin Oncol 21:2004-2010, 2003
21. Le Chevalier T, for the IALT Investigators: Results of the randomized international adjuvant lung cancer trial (IALT): Cisplatin-based chemotherapy (ct) vs. no ct in 1867 patients with resected non-small cell lung cancer. Proc Am Soc Clin Oncol 22:2, 2003 (abstr 6)
22. Kato H, Tsuboi M, Ohta M, et al: A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage 1 adenocarcinoma of the lung. Proc Am Soc Clin Oncol 22:621, 20O3 (abstr 2498)
23. Kris MG, Natale RB, Herbst RS, et al: Efficiency of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer, a randomized trial. JAMA 290:2149-2158, 2003
24. Herbst RS, Maddox AM, Rothenberg MS, et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZDD 1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors; Results of a phase 1 trial. J Clin Oncol 20:3815-3825, 2002
25. Giaccone G, Johnson D, Scagliotti GV, et al: Results of a multivariate analysis of prognostic factors of overall survival of patients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib (ZD1839) in combination with platinum-based chemotherapy (CT) in two large phase III trials (INTACT 1 and 2). Proc Am Soc Clin Oncol 22:627, 2003 (abstr 2522)
26. Perez-Soler R, Burke TG, Liu X, et al: Pre-clinical pharmacology and development of liposomal formulations of the potent topoisomerase I inhibitor. Proc Am Soc Clin Oncol 21:118, 2002 (abstr 469)
27. Khuri FR, Glisson BS, Meyers ML, et al: Phase I study of farnesyl transferase inhibitors (FTI) SCH66336 with paclitaxel in solid tumors. Dose finding, pharmacokinetics, efficacy/safety. Lung Cancer 29:63, 2000 (abstr 205)
28. Khuri FR, Kim ES, Kies MS, et al: A phase I/II study of the farnesyl transferase inhibitor (FTI) SCH66336 (Ionafarnib) with paclitaxel in taxane-refractory/resistant patients with non-small cell lung cancer (NSCLC). Final report. Proc Am Assoc Cancer Res 43:550, 2002 (abstr 2735)
29. Khuri FR, Rigas JR, Figlin RA, et al: Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 19:2626-2637, 2001
30. Lynch TJ, Raju R, Lind M, et al: Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report. Proc Am Soc Clin Oncol 22:623, 2003 (abstr 2504)